Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes Mellitus: The SIDAXA Study-Reference-Cited by-同舟云学术

Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes Mellitus: The SIDAXA Study

Published:2024-05-21 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Chawla Manoj,Panneerselvam Dharmarajan,Gundgurthy Abhay,Sud Sanjay,Alamchandani Ravi,Aneja Pankaj,Nair Rathish,Korukonda Krishnaprasad R

Publisher

Springer Science and Business Media LLC

Reference30 articles.

1. The real DAPSI: a real-world retrospective study on assessing the efficacy and safety of a fixed-dose combination of dapagliflozin and sitagliptin in the Indian population;Bhattacharjee R;Cureus,2023

2. A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of metformin hydrochloride 1000 mg ER, sitagliptin phosphate 100 mg, and dapagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: the MESIDA trial;Singh AK;Int J Diabetes Dev Ctries,2024

3. Dapagliflozin and sitagliptin combination therapy: an overview of clinical utility in type 2 diabetes mellitus with multiple cardiovascular risk factors;Ravikumar L;Cardiol Cardiovasc Med,2023

4. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR);Fuchigami A;Cardiovasc Diabetol,2020

5. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi SE;Diabetes Care,2015